Studying the effect of green tea in MS patients

The Effect of epigallocatchin gallate Enriched Green Tea on some Clinical, Inflammatory, Antioxidant and Cognitive Parameters in Patients with Multiple Sclerosis; A Triple-blind Randomized Placebo Clinical Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180902040927N6

Enrollment

Registered

2026-05-14

Start date

2020-10-06

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Control group: To receive capsules containing vegetable cellulose, magnesium stearate, silica or maltodextrine as a placebo twice daily for 3 months. Intervention 2: Intervention group

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Willingness to participate Confirmation of Relapsing-Remitting Multiple Sclerosis (RRMS) according to the McDonald protocol Expanded Disability Status Scale (EDSS) score below 3.5 Age 20–50 years

Exclusion criteria

Exclusion criteria: Having other neurological and autoimmune diseases Having cancer Allergy to green tea products Current use of antioxidant supplements Regular green tea consumption Adherence to special diets Alcohol or substance abuse Pregnancy and lactation.

Design outcomes

Primary

Measure	Time frame
Cognitive function: working memory and auditory information processing speed. Timepoint: Before the start of the study and 3 months after receiving the drug. Method of measurement: Paced Auditory Serial Addition Test.;Overt and covert anxiety. Timepoint: Before and after three months of taking the drug. Method of measurement: Spielberger Overt and Covert Anxiety Questionnaire.;Scale of Mini mental status test (MMSE). Timepoint: Before and 3 months after the intervention. Method of measurement: Mini mental status test (MMSE).;Depression rate. Timepoint: Before and 3 months after the intervention. Method of measurement: Beck Depression Inventory- II (BDI- II).;Degree of fatigue. Timepoint: Before and 3 months after the intervention. Method of measurement: Fatigue Severity Scale: (FSS).	—

Measure

Time frame

Cognitive function: working memory and auditory information processing speed. Timepoint: Before the start of the study and 3 months after receiving the drug. Method of measurement: Paced Auditory Serial Addition Test.;Overt and covert anxiety. Timepoint: Before and after three months of taking the drug. Method of measurement: Spielberger Overt and Covert Anxiety Questionnaire.;Scale of Mini mental status test (MMSE). Timepoint: Before and 3 months after the intervention. Method of measurement: Mini mental status test (MMSE).;Depression rate. Timepoint: Before and 3 months after the intervention. Method of measurement: Beck Depression Inventory- II (BDI- II).;Degree of fatigue. Timepoint: Before and 3 months after the intervention. Method of measurement: Fatigue Severity Scale: (FSS).

—

Secondary

Measure	Time frame
Interleukin 10. Timepoint: Before the start of the intervention and three months after the start of the intervention. Method of measurement: Karmania Pars Gene Company Kit.;Total antioxidant capacity (TAC). Timepoint: Before the start of the intervention and three months after the start of the intervention. Method of measurement: Karmania Pars Gene Company Kit.;Lower limb motor function assessment. Timepoint: Before the start of the intervention and three months after the start of the intervention. Method of measurement: Timed 25-Foot Walk (T25-FW).;Upper limb motor function assessment. Timepoint: Before the start of the intervention and three months after the start of the intervention. Method of measurement: Nine-Hole Peg Test.;The degree of disability of the MS patient. Timepoint: Before the start of the intervention and three months after the start of the intervention. Method of measurement: Expanded Disability Status Scale (EDSS).;Quality of life. Timepoint: Before the start of the intervention and three months after the start of the intervention. Method of measurement: 36-item Quality of Life Questionnaire (SF-36).	—

Measure

Time frame

Interleukin 10. Timepoint: Before the start of the intervention and three months after the start of the intervention. Method of measurement: Karmania Pars Gene Company Kit.;Total antioxidant capacity (TAC). Timepoint: Before the start of the intervention and three months after the start of the intervention. Method of measurement: Karmania Pars Gene Company Kit.;Lower limb motor function assessment. Timepoint: Before the start of the intervention and three months after the start of the intervention. Method of measurement: Timed 25-Foot Walk (T25-FW).;Upper limb motor function assessment. Timepoint: Before the start of the intervention and three months after the start of the intervention. Method of measurement: Nine-Hole Peg Test.;The degree of disability of the MS patient. Timepoint: Before the start of the intervention and three months after the start of the intervention. Method of measurement: Expanded Disability Status Scale (EDSS).;Quality of life. Timepoint: Before the start of the intervention and three months after the start of the intervention. Method of measurement: 36-item Quality of Life Questionnaire (SF-36).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahdieh Azin

Rafsanjan University of Medical Sciences

mahdieh.azin@gmail.com+98 34 3131 5072

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026